A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.
Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, Herndon JE 2nd, McLendon RE, Pegram CN, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Guruangan S, Boulton S, Raynor RH, Dowell JM, Wong TZ, Zhao XG, Friedman HS, Bigner DD.
Neuro Oncol. 2008 Apr;10(2):182-9. Epub 2008 Feb 20.PMID: 18287339 [PubMed - indexed for MEDLINE]Related articlesFree article